Current Report Filing (8-k)
June 17 2019 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 13, 2019
DELMAR
PHARMACEUTICALS, INC.
|
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
Suite
720-999 West Broadway Vancouver,
British
Columbia, Canada
|
|
V5Z 1K5
|
(Address
of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code:
(604) 629-5989
Not
Applicable
|
(Former name or
former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
Common
Stock
|
|
DMPI
|
|
The
Nasdaq Capital Market
|
Item
8.01. Other Events.
On June 13, 2019, DelMar Pharmaceuticals, Inc.
(the “Company”) received written notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market (the “Nasdaq
Hearings Panel”) informing the Company that, taking into consideration the Company’s registered direct offering of
shares of its common stock and concurrent private placement of warrants to purchase common stock (collectively, the “RD
Offering”) that was consummated on June 5, 2019, resulting in gross proceeds of $3.6 million, and the Company’s pending
rights offering, the Nasdaq Hearings Panel granted the Company’s request for continued listing, subject to the condition
that on or before October 15, 2019, the Company shall have issued public disclosure on Form 8-K that it has over $2.5 million
in stockholders’ equity and demonstrate compliance with all other requirements for continued listing.
As previously disclosed, on May 22, 2019 and
May 23, 2019 the Company received written notices (collectively, the “Notice”) from the Listing Qualifications Department
of Nasdaq indicating that, in light of the Company having reported stockholders’ equity of $1,259,161 as of March 31, 2019
in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, the Company was not in compliance with the $2,500,000
minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq
Capital Market (the “Stockholder’s Equity Requirement”), or with any alternative standard under the Nasdaq Listing
Rules. The Notice requested that the Company present a plan to regain compliance with the above-mentioned deficiency by written
submission no later than May 29, 2019, which the Company submitted within such time period, in order to be considered by the Nasdaq
Hearings Panel that was, until May 23, 2019, considering the Company’s continued listing due to the Company’s previously
cured deficiency with respect to the $1.00 per share bid price requirement, as previously disclosed.
On April 18, 2019, the Company filed a registration
statement in connection with a proposed rights offering for its stockholders to subscribe for shares of the Company’s preferred
stock and accompanying warrants to purchase shares of the Company’s common stock, which registration statement was last amended
on June 10, 2019. The Company expects to utilize the proceeds from the rights offering and the RD Offering towards establishing
compliance with the Stockholder’s Equity Requirement; provided that the Company will need to raise additional capital to
obtain compliance.
There can be no assurance that the Company will
be successful in meeting the Nasdaq Hearings Panel’s conditions, or that the Company will be successful in regaining compliance
with all applicable requirements for continued listing on The Nasdaq Capital Market. The delisting of the Company’s common
stock from a national exchange could materially adversely affect the Company’s access to capital markets, and any limitation
on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect the Company’s
ability to raise capital on terms acceptable to the Company, or at all.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
DELMAR PHARMACEUTICALS, INC.
|
|
|
Date:
June 17, 2019
|
By:
|
/s/
Scott Praill
|
|
|
Name:
Scott Praill
Title: Chief Financial Officer
|
2
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
DelMar Pharmaceuticals (NASDAQ:DMPI)
Historical Stock Chart
From Apr 2023 to Apr 2024